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Introduction 
The massive lymphoid content, and the heavy bac-
terial load of the gut provided formidable barriers to 
intestinal transplantation in humans until the clinical 
introduction of tacrolimus in 1989. After successful 
preclinical studies, large scale trials were successfully 
undertaken at our Institution in 1990. To improve 
outcome and cost effectiveness of the procedure, we 
conducted an outcome analyses trying to identify 
correctable risk factors. Several factors have been 
recently identified that significantly influenced patient 
and graft survival (1-2). Of these, four were major 
immunologic risk factors; the number of episodes of 
intestinal allograft rejections, high blood tacrolimus 
trough levels, high dose steroid requirements, and the 
need for adjunct OKT3 therapy. The remaining sig-
nificant risk factors were number of previous abdominal 
surgeries, operative and cold ischemia times, cytome-
galoviral (CMV), and post-transplant lymphoprolifer-
ative diseases. In order to lower the immunosuppressive 
requirements and improve survival outcome, we de-
clared a one year moratorium in 1994 (figure I), pend-
ing the results of extensive clarifying investigations by 
Murase and associates in rats (3). When the program 
reopened, two major changes in management strategy 
were instituted. One was an attempt to avoid, when 
possible, the transplantation of organs from CMV-
positive donors to CMV -negative recipients. The second 
change was to give perioperative adjunct donor bone 
marrow when this was available, in order to take 
advantage of the more tolerogenic proflie of bone 
marrow cells compared to that of the intestinal pas-
senger leukocytes (3-6). Other adopted strategies were 
careful patient selection, exclusion of the colon from 
the intestinal allograft, and monitoring of EBV infection 
by serial quantitative EBV -PCR measurements. 
Materials and methods 
We report here our overall long-term results with 
121 intestinal transplantation in 115 consecutive patients 
that were transplanted between May 2, 1990 and 
October 8, 1998. Of these 68 (59%) were children and 
47 (41%) were adults. The causes of intestinal failure 
were short gut syndrome (SGS) in 95 (82%), dysmotility 
syndrome in II (10%), intestinal neoplasm in 6 (5%), 
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Fig. I. - Number of intestinal transplants per year at the 
University of Pittsburgh. 
and enterocyte dysfunction in 3 (3%). The leading 
causes of SGS were vascular occlusion (n = 14), 
Crohn's disease (n = 11), and trauma (n = 7) in adults 
and volvulus (n = 20), gastroschisis (n = 16), necrot-
izing enterocolitis (n = 9) and atresia (n = 8) in children. 
The intestine was engrafted alone (n = 43, 37%), or as 
part of a composite graft (n = 76, 63%). The composite 
visceral grafts were combined liver and intestine 
(n = 59) and multivisceral (n = 17). All of the isolated 
intestinal recipients were suffering from frequent central 
line sepsis (30%), vanishing central venous access (40%), 
and reversible TPN induced hepatic dysfunction (30%). 
Most combined liver recipients had TPN induced liver 
failure before transplantation. The donors were all 
ABO identical and HLA histoincompatible. The Iym-
phocytotoxic cross-match was positive in 16 patients. 
No attempts were made to alter the graft lymphore-
ticular tissue with antilymphocyte preparations or other 
modalities. Of the last 61 recipients, 25 were infused 
with bone marrow, the distinction from the other 36 
being the willingness of the donor family to permit the 
extra procurement procedure. The surgical techniques 
of the donor and recipient operation and details of bone 
marrow augmentation are fully described elsewhere 
(7-10). 
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The management of the intestinal allograft recipients 
is fully described elsewhere (II). The immunosuppres-
sive therapy was based on tacrolimus and prednisone. 
Cyclophosphamide was given to 23 patients after the 
moratorium at a dose of 2-3 mg/kg/day for 4 weeks 
and then switched to mycophenolate mofetil (15-30 
mg/ kg/ day) or azathioprine. Daclizumab (Zenapax) 
was given as an induction therapy for the last 8 
recipients in a dose of 1-2 mg/kg body weight every 
two weeks for a total of five doses. In a few cases, 
azathioprine was given as a third maintenance drug 
from the outset. The level of maintenance immuno-
suppression was individualized and adjusted based 
upon the clinical course of each patient with the 
intention to reduce the drug dosage and levels whenever 
possible. Episodes of rejection were treated with ad-
justments of tacrolimus dose and/ or supplemental 
prednisone. OKT3 was given only as a rescue therapy. 
Upward dose adjustments of mycophenolate mofetil, 
azathioprine, or steroids, were frequently needed to 
compensate for tacrolimus dose reductions mandated 
by tacrolimus-related adverse effects. Patient/ graft sur-
vival and curves of cumulative risks were generated 
using the Kaplan-Meier method and group comparisons 
were done using the log-rank test. 
Results 
Survival 
The overall cumulative patient survival is 72% at one 
year and 48% at five years with a graft survival rate 
of 64% and 40% respectively (figure 2). With a mean 
follow-up of 40 ± 29 months (range: 1-94),31 patients 
are alive with good nutrition beyond the third postop-
erative year and 18 are well beyond the 5-year mile 
stone. The survival benefits of intestinal transplantation 
has been better (p = 0.57) achieved among children 
compared to adults with the best outcome among 
patients between 2 and 17 years of age, in whom the 
5 year cumulative survival rate was 68%. Bone marrow 
1.11 
n." 
~ fUI 
.. 
t tl5 
:: 
~ ffK~ 
n .. ' 
11.2 
n.1 
11.11 
II 
JJ 
I. _ 
31 
Patient (N=IIS) 
Graft (N=121) 
I ~ ~ .j 
Time After Transplantation (years) 
211 
II! 
Fig. 2. - Patient and graft survival curves using the Kaplan-
Meier method. 
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Fig. 3. - Patient survival and bone marrow augmentation. 
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Fig. 4. - Cumulative risk of graft loss due to rejection among 
isolated and composite intestinal grafts. 
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Fig. 5. - Effect of type of venous drainage on intestinal 
allograft survival. 
augmentation did not significantly improve patient 
survival (figure 3). Although both the isolated intestinal 
and composite visceral grafts had similar (p = 0.72) 
survival rate, the cumulative risk of graft loss due to 
rejection was significantly (p = 0.045) higher among the 
isolated intestine (figure 4). Systemic venous drainage 
of the isolated intestine did not significantly affect graft 
survival (figure 5). The Kaplan-Meier graft survival 
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curves stratified according to the etiology of intestinal 
failure are depicted in figure 6. The best survival rates 
have been achieved among children with microvillus 
disease and gastroschisis and in adults with Crohn's 
disease and vascular thrombosis. Figure 7 illustrates 
the significant (p = 0.04) improvement in intestinal 
allograft survival during the last four years (after the 
moratorium) with a cumulative rate of 65% at four 
years. Such an achievement reflects further refinement 
in operative techniques, immunomodulation. and man-
agement strategies as described above. 
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Fig. 7. - Causes of intestinal failure and patient survival. 
Long-term rehabilitation 
Fifty-eight (95%) of the 61 current survivors are 
home. fully active and completely off TPN with full 
nutritional autonomy. These individuals have reported 
improved qUality of life measures in comparison to 
TPN dependency. The remaining three patients (5%) 
are receiving partial intravenous support while recov-
ering from a recent episode of rejection (n = 2) or 
PTLD (n = I). No clinical or histopathologic evidences 
of disease recurrence has been documented in our series 
during the 8 years of follow-up. To date. no attempts 
have been made to electively wean any of the intestinal 
recipients. including the bone marrow augmented cases. 
off immunosuppression. 
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Cost Analysis 
The average cost of intestinal transplantation between 
1990 and 1994 was $203,1l1 for the isolated intestine, 
$252,453 for the combined liver-intestine transplanta-
tion, and $284,452 for the multivisceral procedure. This 
has been significantly reduced during the last four years 
to an average of $132,285, $214,716 and $219,098, 
respectively. The use of intestinal transplant can be 
examined on a cost-effectiveness basis, due to the 
availability of chronic TPN as an alternative therapy 
for patients with irreversible gut failure. Based on the 
Medicare (USA) data, the average yearly cost of TPN 
in 1992 was above $150,000 per patient not including 
the cost of frequent hospita1ization, medical equipment, 
and nursing care (12). The total dollars spent on TPN 
are increasing every year because of the yearly increase 
in TPN cost and the cumulative increase of the home 
and hospital bound TPN popUlation. Based upon these 
data, intestinal transplantation becomes cost-effective 
by the second year after transplantation . 
Conclusions 
Intestinal transplantation has become a life saving 
treatment for patients with irreversible intestinal failure 
who cannot be maintained on TPN, and a cost effective 
therapy for patients who still have the option of TPN. 
The long-term rehabilitation with all three kinds of 
intestinal transplantation is similar to that achieved 
with lung transplantation (13), and some other kinds 
of organ allografts. Therefore, it is justifiable, to cur-
rently consider intestinal transplantation as non-exper-
imental procedure. Based upon the results of our most 
recent preclinical trials (14), further improvement in 
patient and graft survival is greatly anticipated with 
further immune modulation strategies (graft cytoreduc-
tion) that can be added to the bone marrow augmen-
tation protocol. 
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